

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION  
(Translated from Hebrew)

	March 31		December 31
	2021	2020	2020
	NIS in thousands		
<b>Assets</b>			
<b>CURRENT ASSETS:</b>			
Cash and cash equivalents	22,008	27,835	25,532
Receivables:			
Trade receivables	7,507	5,208	7,862
Other receivables	13,103	971	9,053
Current tax assets	1,034	843	-
Inventory	19,993	11,919	19,977
Biological assets	2,126	2,887	1,866
	<u>65,771</u>	<u>49,663</u>	<u>64,290</u>
<b>NON-CURRENT ASSETS:</b>			
Property, plant and equipment	11,830	10,317	11,706
Operating lease right of use assets	2,188	1,796	2,021
Investments in associates	5,447	1,332	5,461
Financial assets	12,198	4,800	9,496
	<u>31,663</u>	<u>18,245</u>	<u>28,684</u>
<b>TOTAL ASSETS</b>	<b><u>97,434</u></b>	<b><u>67,908</u></b>	<b><u>92,974</u></b>
<b>Liabilities and equity</b>			
<b>CURRENT LIABILITIES -</b>			
Accounts payable:			
Trade payables	1,021	960	1,045
Other payables	3,937	2,068	3,699
Deferred and contingent liabilities	4,748	11,212	4,748
	<u>9,706</u>	<u>14,240</u>	<u>9,492</u>
<b>NON-CURRENT LIABILITIES:</b>			
Deferred tax liability	2,475	2,822	2,363
Operating lease liabilities	1,929	1,264	1,754
Retirement benefits liabilities, net	115	113	115
	<u>4,519</u>	<u>4,199</u>	<u>4,232</u>
<b>EQUITY:</b>			
Share capital and share premium	62,140	49,430	62,140
Other equity reserves	9,687	2,150	9,053
Accumulated earnings (loss)	11,382	(2,111)	8,057
	<u>83,209</u>	<u>49,469</u>	<u>79,250</u>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b><u>97,434</u></b>	<b><u>67,908</u></b>	<b><u>92,974</u></b>

# Seach\*

MEDICAL GROUP

## CONSOLIDATED INCOME STATEMENTS

(Translated from Hebrew)

	THREE MONTHS ENDED IN		YEAR ENDED IN
	2021	2020	2020
	NIS in thousands		
Revenue from sales	10,998	7,666	36,802
Cost of sales	6,487	2,376	15,698
<b>GROSS PROFIT BEFORE FAIR VALUE ADJUSTMENTS</b>	<b>4,511</b>	<b>5,290</b>	<b>21,104</b>
Unrealized gain on changes in fair value of biological assets	1,594	2,386	6,695
Fair value changes in biological assets sold	(1,354)	(2,824)	(10,857)
<b>GROSS PROFIT AFTER FAIR VALUE ADJUSTMENTS</b>	<b>4,751</b>	<b>4,852</b>	<b>16,942</b>
Research and development expenses	574	548	1,925
Sales and marketing expenses	1,331	640	3,003
General and administrative expenses	1,529	2,099	7,570
Loss from disposal and decrease in holding stake in associates	348	236	1,552
Other income	(19)	2,388	(5,767)
<b>OPERATING INCOME (LOSS)</b>	<b>988</b>	<b>3,717</b>	<b>8,659</b>
Finance expenses	60	2,181	707
Finance income	2,767	289	5,347
Financial income (expenses), net	2,707	(1,892)	4,640
<b>INCOME (LOSS) BEFORE TAXES</b>	<b>3,695</b>	<b>1,825</b>	<b>13,299</b>
Tax expenses	370	26	1,332
<b>NET INCOME (LOSS)</b>	<b>3,325</b>	<b>1,799</b>	<b>11,967</b>
<b>OTHER COMPREHENSIVE INCOME (LOSS)</b>			
Items that will be reclassified into profit or loss -			
Translation differences, net	(58)	-	28
Items that will not be reclassified into profit or loss -			
Profit (loss) from financial assets at fair value, net of tax	278	512	565
<b>TOTAL OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX</b>	<b>220</b>	<b>512</b>	<b>593</b>
<b>TOTAL COMPREHENSIVE PROFIT (LOSS)</b>	<b>3,545</b>	<b>2,311</b>	<b>12,560</b>
<b>PROFIT (LOSS) PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY:</b>			
Basic and diluted	0.01	0.01	0.04